Background Direct oral anticoagulants (DOAC) use remains challenging in obese patients
treated for Venous-Thrombo-Embolism (VTE) due to the paucity of prospective and …

Introduction Limited data exist on direct-acting oral anticoagulants in morbidly obese
patients with venous thromboembolism (VTE). We compared clinical and health/economic …

There is limited data evaluating clinical outcomes of rivaroxaban versus warfarin in obese
patients with venous thromboembolism (VTE). Our objective was to evaluate the …

This study integrated 5 United States healthcare claims databases to evaluate the risk of
recurrent venous thromboembolism (VTE) and major bleeding (MB) among VTE patients …

Introduction As a result of limited clinical data, guidelines do not recommend the use of non-
vitamin K antagonist oral anticoagulants in patients who weigh> 120 kg or have a body …

Background Rivaroxaban is a first-line option for the management of venous
thromboembolism (VTE). However, limited data are available regarding its effectiveness in …

Abstract Study Objective Direct oral anticoagulants are the standard of care for venous
thromboembolism (VTE) treatment. These agents are recommended regardless of patient …

Background There is scarce evidence on the effectiveness and safety of recommended-
dose direct acting oral anticoagulants (DOACs) in obese patients with venous …

Obesity plays an essential role in the safety of pharmacologic drugs. There is paucity of data
for direct oral anticoagulants (DOACs) in the obese, despite these agents becoming more …

Background: In patients with venous thromboembolism (VTE), warfarin had been considered
standard of care until the new direct oral anticoagulants (DOACs) were developed. Studies …